Does a pre-revenue clinical-stage biotech need D&O insurance?

D&O insurance is often misframed as protecting against shareholder lawsuits — relevant only after IPO or material commercial activity. The framing is incomplete. Pre-revenue biotechs face three D&O exposures from the day of incorporation: (1) investor disputes (preferred shareholders, convertible note holders, SAFE investors challenging decisions), (2) regulatory investigations (FDA in the clinical trial setting, SEC for any private placement materials), and (3) employment-based claims against individual directors and officers.

Each of these exposures can produce six- to seven-figure defense costs even if the underlying claim is meritless. Without D&O coverage, those defense costs fall on the individual directors and officers personally — or on the company's working capital if it chooses to indemnify.

Convertible note holders, SAFE investors, and preferred shareholders sometimes dispute company decisions: down-rounds, pivots, founder removal, or any decision that affects investor economics. The disputes typically name individual directors as defendants alongside the company, which puts personal assets at risk if the company cannot indemnify.

This exposure rises sharply at financing rounds (where new investor preferences can dilute existing rights) and at clinical inflection points (where a failed trial can trigger value-loss disputes). Even amicable rounds occasionally produce post-hoc disputes that require D&O defense.

FDA investigations of clinical trial conduct, IND submission accuracy, and informed consent practices can name individual investigators and corporate officers. SEC investigations of private placement memoranda, accredited investor verification, and investor communications can also name individual signatories of disclosure documents.

Standard biotech D&O policies cover defense costs in both FDA and SEC investigations, with sub-limits sized to expected investigation costs ($500K-$2M typical). For pre-revenue biotechs running clinical trials, the FDA investigation exposure is meaningful and the policy is the primary funding source for defense.

Wrongful termination, discrimination, and retaliation claims against individual directors and officers (in addition to the company) are increasingly common. EPLI typically covers the company, but Side B and Side C D&O coverage extends to the individuals.

For pre-revenue biotechs with small headcounts, the per-employee exposure is concentrated. A single C-suite-level wrongful termination claim can produce $250K-$1M defense costs before any settlement.

Pre-revenue biotechs often have constrained working capital and may be unable to indemnify directors and officers in a dispute. Side A coverage (also called "Difference in Conditions" or DIC) protects individual directors when the company is unwilling or unable to indemnify — typically because of insolvency, regulatory bar on indemnification, or contractual constraint.

For pre-revenue biotechs, Side A is the most important D&O coverage component. Without it, directors face personal asset exposure in scenarios where the company cannot help. Standard policies include Side A as part of the policy form, but some only at sub-limits; verify Side A wording and limits.

Pre-revenue clinical-stage biotechs typically carry $3M-$10M D&O at premiums of $15,000-$60,000 annually depending on stage, clinical pipeline, board composition, and prior investor disputes. The cost is modest relative to the personal-asset protection it provides directors and officers, and is generally treated as a required operating expense rather than discretionary.